THE EVALUATION OF THE EFFECTIVENESS AND SAFETY OF THE USE OF FIXED TRIPLE ORAL SUGAR-REDUCING THERAPY WITH DEBISTAL-GM IN PATIENTS WITH TYPE 2 DIABETES WITH OBESITY

RAKHIMOVA Gulnara Nishanovna, AHROROV Kamil Ubaydullayevich

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali · 2022-yil

Annotatsiya

Given the complexity and versatility of the pathogenesis of type 2 diabetes, the choice of antihyperglycemic drugs is based on the importance of a simultaneous combined effect on several links in the pathogenesis of type 2 diabetes.  The aim of the study was to study the hypoglycemic efficacy, clinical tolerance and safety of Debistal-GM in obese patients with type 2 diabetes.  As a result of the study, high clinical efficacy, good tolerability and safety of Debistal-GM in obese type 2 diabetes were established. Inclusion criteria for the use of Debistal-GM are patients with type 2 diabetes with glycated hemoglobin values ​​above 9%, but below 11%; with a diabetes duration of more than 5 years, with a body mass index of more than 30 kg / m 2.  

Maqola ma’lumotlari
MualliflarRAKHIMOVA Gulnara Nishanovna, AHROROV Kamil Ubaydullayevich
JurnalJournal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali
Nashr sanasi2022-05-31
Jild7
Son2
TilRus

Kalit so‘zlar

сахарный диабет 2 типа, пиоглитазон, фиксированная комбинированная терапия СД 2 типа, трёхкомпонентная антигипер-гликемическая терапия, type 2 diabetes mellitus, pioglitazone, fixed combination therapy for type 2 diabetes, triple antihyperglycemic therapy, қандли диабет 2-тур, пиоглитазон, ҚД 2-турнинг фиксацияланган комбинирланган давоси, уч таркибли антигипрегликемик даво

Ilmiy soha

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali jurnalidan boshqa maqolalar

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali — barcha maqolalar